JPH09509837A - 炎症性疾患の処置のための抗il−8モノクローナル抗体 - Google Patents
炎症性疾患の処置のための抗il−8モノクローナル抗体Info
- Publication number
- JPH09509837A JPH09509837A JP7523020A JP52302095A JPH09509837A JP H09509837 A JPH09509837 A JP H09509837A JP 7523020 A JP7523020 A JP 7523020A JP 52302095 A JP52302095 A JP 52302095A JP H09509837 A JPH09509837 A JP H09509837A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- human
- fab
- antibodies
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.以下の特性:約1x10-8ないし約1x10-10Mの間のKdでヒトIL− 8に結合する能力、IL−8に応答した好中球走化性を阻害する能力、および好 中球によるIL−8仲介性エラスターゼ放出を阻害する能力を有する抗IL−8 モノクローナル抗体(ここで、該モノクローナル抗体はC5a、β−TGまたは 血小板因子4に結合しない)。 2.該抗体がウサギIL−8およびヒトIL−8に約1x10-8ないし約1x 10-10Mの間のKdで結合する、請求項1に記載の抗体。 3.該抗体がモノクローナル抗体6G4.2.5である、請求項2に記載の抗 体。 4.該抗体がモノクローナル抗体5.12.14である、請求項1に記載の抗 体。 5.該抗体がキメラである、請求項1に記載の抗体。 6.該抗体がヒト化されている、請求項1に記載の抗体。 7.該抗体が5.12.14の軽鎖および重鎖可変アミノ酸配列を有する、請 求項1に記載の抗体。 8.該抗体が5.12.14の相補性決定領域を有する、請求項1に記載の抗 体。 9.該抗体が6G4.2.5の軽鎖および重鎖可変アミノ酸配列を有する、請 求項1に記載の抗体。 10.該抗体が6G4.2.5の相補性決定領域を有する、請求項1に記載の 抗体。 11.プラスミドpantiIL−8.2。 12.pantiIL−8.2によりコードされているFab。 13.Fab、Fab'、Fab'−SH、Fv、またはF(ab')2[ここで 、この抗体フラグメントはpantiIL−8.2によりコードされている相補 性決定領域を有する]より成る群から選ばれる抗体フラグメント。 14.該抗体フラグメントがヒト化されている、請求項13に記載の抗体フラ グメント。 15.プラスミドp6G425chim2。 16.p6G425chim2によりコードされているFab。 17.Fab、Fab'、Fab'−SH、Fv、またはF(ab')2[ここで 、この抗体フラグメントはp6G425chim2によりコードされている相補 性決定領域を有する]より成る群から選ばれる抗体フラグメント。 18.該抗体フラグメントがヒト化されている、請求項17に記載の抗体フラ グメント。 19.請求項1に記載の抗体の治療的有効量を哺乳動物に投与することからな る、哺乳動物における潰瘍性大腸炎を処置する方法。 20.哺乳動物が人間である、請求項19に記載の方法。 21.該抗体が全身的に投与される、請求項19に記載の方法。 22.該抗体が持続的注入により投与される、請求項19に記載の方法。 23.該組成物がボーラス投与により投与される、請求項19に記載の方法。 24.該抗体が6G4.2.5の相補性決定領域を有する、請求項19に記載 の方法。 25.該抗体が5.12.14の相補性決定領域を有する、請求項19に記載 の方法。 26.請求項1に記載の抗体の治療的有効量を哺乳動物に投与することからな る、哺乳動物における細菌性肺炎を処置する方法。 27.哺乳動物が人間である、請求項26に記載の方法。 28.細菌性肺炎が、ストレプトコッカス・ニューモニア、エシェリチア・コ リ、またはシュードモナス・アエルギノーサにより惹起される、請求項26に記 載の方法。 29.該抗体が6G4.2.5の相補性決定領域を有する、請求項26に記載 の方法。 30.該抗体が5.12.14の相補性決定領域を有する、請求項26に記載 の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20586494A | 1994-03-03 | 1994-03-03 | |
US08/205,864 | 1994-03-03 | ||
PCT/US1995/002589 WO1995023865A1 (en) | 1994-03-03 | 1995-03-01 | Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09509837A true JPH09509837A (ja) | 1997-10-07 |
JP3780315B2 JP3780315B2 (ja) | 2006-05-31 |
Family
ID=22763963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52302095A Expired - Fee Related JP3780315B2 (ja) | 1994-03-03 | 1995-03-01 | 炎症性疾患の処置のための抗il−8モノクローナル抗体 |
Country Status (6)
Country | Link |
---|---|
US (4) | US5702946A (ja) |
EP (1) | EP0749488A1 (ja) |
JP (1) | JP3780315B2 (ja) |
CA (1) | CA2181787A1 (ja) |
MX (1) | MX9603773A (ja) |
WO (1) | WO1995023865A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013523182A (ja) * | 2010-04-15 | 2013-06-17 | アボット・ラボラトリーズ | アミロイドベータ結合タンパク質 |
JP2020521799A (ja) * | 2017-05-30 | 2020-07-27 | ドンペ ファーマスーチシ ソシエタ ペル アチオニ | 細菌性二次感染の治療および/または予防における使用のためのil−8阻害剤 |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5874080A (en) * | 1994-03-03 | 1999-02-23 | Genentech, Inc. | Anti-IL-8 monoclonal antibodies for treatment of asthma |
EP0770628B9 (en) * | 1994-07-13 | 2007-02-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
US5997496A (en) * | 1995-07-10 | 1999-12-07 | Asahi Medical Co., Ltd. | System and method of extracorporeally treating blood to alleviate the symptoms of inflammatory diseases |
US5853697A (en) * | 1995-10-25 | 1998-12-29 | The United States Of America, As Represented By The Department Of Health & Human Services | Methods of treating established colitis using antibodies against IL-12 |
WO1997039772A1 (fr) * | 1996-04-19 | 1997-10-30 | Chugai Seiyaku Kabushiki Kaisha | Remede contre l'arthrite rhumatoide contenant un anticorps anti-il-8 comme principe actif |
EP0966971A1 (en) * | 1996-04-23 | 1999-12-29 | Chugai Seiyaku Kabushiki Kaisha | Cerebral stroke/cerebral edema preventive or remedy containing il-8 binding inhibitor as active ingredient |
WO1997049426A1 (fr) * | 1996-06-26 | 1997-12-31 | Chugai Seiyaku Kabushiki Kaisha | Medicaments destines aux lesions pulmonaires aigues dues a des causes indirectes, contenant un anticorps anti-il-8 comme principe actif |
AU3048797A (en) * | 1996-10-22 | 1998-05-15 | Chugai Seiyaku Kabushiki Kaisha | Sepsis remedy comprising anti-il-8 antibody as active ingredient |
JP4215172B2 (ja) | 1996-12-03 | 2009-01-28 | アムジェン フレモント インク. | 複数のV▲下H▼およびV▲下κ▼領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
US6025158A (en) * | 1997-02-21 | 2000-02-15 | Genentech, Inc. | Nucleic acids encoding humanized anti-IL-8 monoclonal antibodies |
US7122636B1 (en) | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US6117980A (en) * | 1997-02-21 | 2000-09-12 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
US6133426A (en) * | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
ES2215295T3 (es) | 1997-02-21 | 2004-10-01 | Genentech, Inc. | Conjugados de polimeros y fragmentos de anticuerpo. |
JP4550171B2 (ja) * | 1997-04-11 | 2010-09-22 | サングスタット メディカル コーポレイション | 免疫系活性を調節する及び炎症を阻害するための細胞調節親油性ペプチド |
US7147854B2 (en) * | 1997-06-23 | 2006-12-12 | Yes Biotech Laboratories Ltd. | Topical treatment of psoriasis using neutralizing antibodies to interleukin-8 |
US7005504B2 (en) * | 1998-01-22 | 2006-02-28 | Genentech, Inc. | Antibody fragment-peg conjugates |
US6468532B1 (en) | 1998-01-22 | 2002-10-22 | Genentech, Inc. | Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates |
AU2559799A (en) * | 1998-01-22 | 1999-08-09 | Genentech Inc. | Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same |
US6458355B1 (en) | 1998-01-22 | 2002-10-01 | Genentech, Inc. | Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates |
IL137649A (en) * | 1998-02-18 | 2004-08-31 | Genentech Inc | Method of adsorption chromatography |
CA2325338C (en) * | 1998-04-10 | 2015-06-23 | Andrew Lees | Conjugate vaccines for the prevention of dental caries |
US6395273B1 (en) | 1998-06-10 | 2002-05-28 | Promega Corporation | Prevention and treatment of inflammatory bowel disease |
CA2403371A1 (en) * | 2000-02-10 | 2001-08-16 | Timothy F. Murphy | A method for detecting bacterial exacerbations of chronic lung disease |
AR030753A1 (es) * | 2000-09-25 | 2003-09-03 | Smithkline Beecham Corp | Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas |
TWI313299B (en) | 2000-11-30 | 2009-08-11 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
DE60227067D1 (de) | 2001-05-11 | 2008-07-24 | Kirin Pharma Kk | Künstliches menschliches chromosom mit dem gen für die lambda-leichte kette menschlicher antikörper |
DE60325334D1 (de) | 2002-02-05 | 2009-01-29 | Genentech Inc | Proteinaufreinigung |
EP1494711A4 (en) * | 2002-03-19 | 2008-05-28 | Abgenix Inc | METHODS FOR TREATING CHRONIC OBSTRUCTIVE BRONCHO PNEUMOPATHY (COPD) |
AUPS160602A0 (en) * | 2002-04-08 | 2002-05-16 | University Of Queensland, The | Therapeutic method |
JP4319979B2 (ja) | 2002-04-26 | 2009-08-26 | ジェネンテック・インコーポレーテッド | タンパク質の非アフィニティ精製 |
EP1558277B1 (en) * | 2002-10-16 | 2011-05-18 | Promics Pty Limited | Treatment of inflammatory bowel disease |
AU2002952086A0 (en) * | 2002-10-16 | 2002-11-07 | The University Of Queensland | Treatment of osteoarthritis |
ES2373947T3 (es) * | 2002-12-16 | 2012-02-10 | Genmab A/S | Anticuerpos monoclonales humanos contra interleucina 8 (il-8). |
GB0306618D0 (en) * | 2003-03-22 | 2003-04-30 | Univ Newcastle | Antibody |
WO2005003174A1 (en) * | 2003-07-08 | 2005-01-13 | Genesto A/S | BINDING MEMBER TOWARDS PNEUMOCOCCUS SURFACE ADHESIN A PROTEIN (PsaA) |
DK3095793T3 (da) | 2003-07-28 | 2020-05-25 | Genentech Inc | Reducering af udvaskning af protein A under en protein A-affinitetskromatografi |
WO2005074417A2 (en) * | 2003-09-03 | 2005-08-18 | Salk Institute For Biological Studies | Multiple antigen detection assays and reagents |
ES2382627T3 (es) * | 2004-06-29 | 2012-06-12 | B.R.A.H.M.S Gmbh | Nuevos anticuerpos monoclonales estimuladores o bloqueadores de la tiroides, secuencias peptídicas que corresponden a sus regiones variables, y sus usos en medicina diagnóstica, preventiva y terapéutica |
US7662926B2 (en) | 2004-09-02 | 2010-02-16 | Genentech, Inc. | Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor |
US7655229B2 (en) | 2004-09-02 | 2010-02-02 | Chan Andrew C | Anti-FC-gamma RIIB receptor antibody and uses therefor |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
MX2007013058A (es) * | 2005-04-20 | 2008-02-22 | Amgen Fremont Inc | Anticuerpos monoclonales de alta afinidad completamente humanos para interleucina-8 y epitopes para dichos anticuerpos. |
WO2007056113A2 (en) * | 2005-11-02 | 2007-05-18 | Cylene Pharmaceuticals, Inc. | Methods for targeting quadruplex sequences |
CA2638774C (en) | 2006-03-31 | 2015-11-24 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
EP2815768A3 (en) * | 2006-04-05 | 2015-01-14 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
FR2902799B1 (fr) | 2006-06-27 | 2012-10-26 | Millipore Corp | Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide |
WO2008079280A1 (en) | 2006-12-21 | 2008-07-03 | Millipore Corporation | Purification of proteins |
US8362217B2 (en) | 2006-12-21 | 2013-01-29 | Emd Millipore Corporation | Purification of proteins |
US8569464B2 (en) | 2006-12-21 | 2013-10-29 | Emd Millipore Corporation | Purification of proteins |
WO2008091740A2 (en) | 2007-01-22 | 2008-07-31 | Genentech, Inc. | Polyelectrolyte precipitation and purification of antibodies |
US8097422B2 (en) | 2007-06-20 | 2012-01-17 | Salk Institute For Biological Studies | Kir channel modulators |
ES2751022T3 (es) | 2007-07-09 | 2020-03-30 | Genentech Inc | Prevención de la reducción de enlaces disulfuro durante la producción recombinante de polipéptidos |
US20100291108A1 (en) * | 2007-10-16 | 2010-11-18 | Arie Abo | Antibodies to irem-1 |
HUE037409T2 (hu) | 2007-10-30 | 2018-08-28 | Genentech Inc | Antitest-tisztítás kationcserés kromatográfiával |
CA2713716A1 (en) * | 2008-02-22 | 2009-08-27 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
GB0806812D0 (en) * | 2008-04-15 | 2008-05-14 | Univ Leuven Kath | Citrullinated cytokines |
WO2009151514A1 (en) | 2008-06-11 | 2009-12-17 | Millipore Corporation | Stirred tank bioreactor |
KR20180033311A (ko) | 2008-08-14 | 2018-04-02 | 제넨테크, 인크. | 고유 단백질 대체 이온 교환 막 크로마토그래피를 이용한 오염물의 제거 방법 |
MX2011002372A (es) | 2008-09-10 | 2011-04-04 | Genentech Inc | Composiciones y metodos para la prevencion de la degradacion oxidativa de proteinas. |
MX2011003246A (es) * | 2008-10-09 | 2011-04-21 | Hoffmann La Roche | Moduladores de beta amiloide. |
JP5378532B2 (ja) * | 2008-11-10 | 2013-12-25 | エフ.ホフマン−ラ ロシュ アーゲー | 複素環γ−セクレターゼモジュレーター |
US20100190963A1 (en) | 2008-12-16 | 2010-07-29 | Millipore Corporation | Stirred Tank Reactor And Method |
US20110020327A1 (en) | 2008-12-16 | 2011-01-27 | Millipore Corporation | Purification of proteins |
WO2010087994A2 (en) | 2009-01-30 | 2010-08-05 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
SG173812A1 (en) | 2009-02-27 | 2011-09-29 | Genentech Inc | Methods and compositions for protein labelling |
KR20180010324A (ko) | 2009-08-11 | 2018-01-30 | 제넨테크, 인크. | 글루타민-비함유 세포 배양 배지에서의 단백질의 생성 |
MX2012002565A (es) | 2009-09-01 | 2012-05-29 | Genentech Inc | Purificacion de proteina mejorada a traves de una elucion de proteina a modificada. |
US20110190269A1 (en) * | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
WO2011095596A1 (en) | 2010-02-04 | 2011-08-11 | Vivalis | Fed-batch process using concentrated cell culture medium for the efficient production of biologics in eb66 cells |
US8486967B2 (en) * | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
CA2792125C (en) | 2010-03-22 | 2019-02-12 | Genentech, Inc. | Compositions and methods useful for stabilizing protein-containing formulations |
BR112012027828A2 (pt) | 2010-05-03 | 2016-08-09 | Genentech Inc | composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína |
US20130108646A1 (en) | 2010-05-04 | 2013-05-02 | Medimmune, Llc | Optimized degenerative muscle disease diagnostics and treatments |
CN107312062B (zh) | 2010-05-17 | 2021-03-16 | Emd密理博公司 | 用于纯化生物分子的刺激响应性聚合物 |
HUE030820T2 (en) | 2010-05-28 | 2017-06-28 | Hoffmann La Roche | Decreasing Lactate Levels and Enhancing Polypeptide Production by Control of Lactate Dehydrogenase and Pyruvate Dehydrogenase Kinase Expression |
EP3586826B1 (en) | 2010-06-24 | 2021-05-12 | F. Hoffmann-La Roche AG | Compositions and methods for stabilizing protein-containing formulations |
BR112013003279A2 (pt) | 2010-08-13 | 2016-06-14 | Genentech In | “métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal” |
WO2012030512A1 (en) | 2010-09-03 | 2012-03-08 | Percivia Llc. | Flow-through protein purification process |
WO2012095514A1 (en) | 2011-01-14 | 2012-07-19 | Vivalis | Recombinant protein production system |
US10006879B2 (en) | 2011-04-12 | 2018-06-26 | Electronic Biosciences, Inc. | Site specific chemically modified nanopore devices |
IL267585B (en) | 2011-12-22 | 2022-09-01 | Genentech Inc | Ion exchange membrane chromatography |
AR090340A1 (es) | 2012-03-27 | 2014-11-05 | Genentech Inc | Operaciones de cosecha mejoradas para proteinas recombinadas |
ES2682761T3 (es) | 2012-05-18 | 2018-09-21 | Genentech, Inc. | Formulaciones de anticuerpos monoclonales de alta concentración |
WO2013192178A1 (en) | 2012-06-18 | 2013-12-27 | Electronic Biosciences Inc. | Cell-free assay device and methods of use |
CA2898146C (en) | 2012-12-19 | 2020-12-01 | Charles Andrew BOSWELL | Methods and compositions for radiohalogen protein labeling |
KR101458947B1 (ko) * | 2013-03-05 | 2014-11-12 | 국립암센터 | 인터루킨-8 앱타머 및 이의 용도 |
MX2017000231A (es) | 2014-07-09 | 2017-06-27 | Genentech Inc | Ajuste del ph para mejorar la recuperacion por descongelamiento de bancos de celulas. |
WO2016172769A1 (en) | 2015-04-29 | 2016-11-03 | University Of South Australia | Compositions and methods for administering antibodies |
EP4218833A1 (en) | 2015-10-01 | 2023-08-02 | Whitehead Institute for Biomedical Research | Labeling of antibodies |
CA3019373A1 (en) | 2016-03-29 | 2017-10-05 | Geltor, Inc. | Expression of proteins in gram-negative bacteria wherein the ratio of periplasmic volume to cytoplasmic volume is between 0.5:1 and 10:1 |
IL267439B2 (en) | 2016-12-22 | 2023-02-01 | Genentech Inc | Methods and formulations for reducing reconstitution time of lyophilized polypeptides |
US11180541B2 (en) | 2017-09-28 | 2021-11-23 | Geltor, Inc. | Recombinant collagen and elastin molecules and uses thereof |
BR112020013144A2 (pt) | 2018-01-12 | 2020-12-08 | Bristol-Myers Squibb Company | Terapia de combinação com anticorpos anti-il-8 e anti-corpos anti-pd-1 para tratamento do câncer |
CN112119098A (zh) | 2018-03-28 | 2020-12-22 | 田边三菱制药株式会社 | cMET单克隆结合剂的药物缀合物及其用途 |
SI3818078T1 (sl) | 2018-07-03 | 2024-05-31 | Bristol-Myers Squibb Company | Postopki za proizvodnjo rekombinantnih proteinov |
CN113166695A (zh) | 2018-10-10 | 2021-07-23 | 勃林格殷格翰国际公司 | 用于高密度生物反应器培养中的膜气体转移的方法 |
MX2021012032A (es) | 2019-04-01 | 2021-11-03 | Genentech Inc | Composiciones y metodos para estabilizar formulaciones que contienen proteinas. |
TW202104254A (zh) | 2019-04-12 | 2021-02-01 | 美商格爾托公司 | 重組彈性蛋白及其生產 |
EP4007808A1 (en) | 2019-08-01 | 2022-06-08 | Bristol-Myers Squibb Company | Methods of improving protein productivity in fed-batch cell cultures |
WO2022066595A1 (en) | 2020-09-22 | 2022-03-31 | Bristol-Myers Squibb Company | Methods for producing therapeutic proteins |
WO2023015234A1 (en) | 2021-08-05 | 2023-02-09 | Bristol-Myers Squibb Company | Cell culture methods for producing therapeutic proteins |
WO2023049687A1 (en) | 2021-09-21 | 2023-03-30 | Bristol-Myers Squibb Company | Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5229275A (en) * | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
PT98072B (pt) * | 1990-06-22 | 1998-11-30 | Chiron Corp | Processo para a preparacao de polipeptidos contendo proteina macrofagica inflamatoria humana mip-2 alfa por metodos recombinantes e de composicoes farmaceuticas que os contem |
US5234911A (en) * | 1990-07-09 | 1993-08-10 | Gist-Brocades, N.V. | Substance with interleukin-8 inhibiting activity and process for its preparation |
IE913192A1 (en) * | 1990-09-12 | 1992-02-25 | Scripps Research Inst | Active site of interleukin-8: polypeptide analogs and¹antibodies |
ATE178942T1 (de) * | 1990-09-28 | 1999-04-15 | Chiron Corp | Verwendung von gro-genen und proteinen |
WO1992006697A1 (en) * | 1990-10-23 | 1992-04-30 | Repligen Corporation | Anti-inflammatory composition |
AU8910891A (en) * | 1990-11-20 | 1992-06-11 | National Heart & Lung Institute, The | Treatment of lung diseases |
JPH0597A (ja) * | 1991-06-21 | 1993-01-08 | Snow Brand Milk Prod Co Ltd | 新規抗tcf−iiモノクローナル抗体及びそれを用いるtcf−iiの測定方法 |
EP0770628B9 (en) * | 1994-07-13 | 2007-02-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
-
1995
- 1995-03-01 MX MX9603773A patent/MX9603773A/es not_active IP Right Cessation
- 1995-03-01 JP JP52302095A patent/JP3780315B2/ja not_active Expired - Fee Related
- 1995-03-01 US US08/398,611 patent/US5702946A/en not_active Expired - Fee Related
- 1995-03-01 CA CA002181787A patent/CA2181787A1/en not_active Abandoned
- 1995-03-01 US US08/398,613 patent/US5677426A/en not_active Expired - Fee Related
- 1995-03-01 WO PCT/US1995/002589 patent/WO1995023865A1/en not_active Application Discontinuation
- 1995-03-01 EP EP95912679A patent/EP0749488A1/en not_active Withdrawn
- 1995-03-01 US US08/398,612 patent/US5686070A/en not_active Expired - Fee Related
- 1995-03-01 US US08/396,851 patent/US5707622A/en not_active Expired - Fee Related
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013523182A (ja) * | 2010-04-15 | 2013-06-17 | アボット・ラボラトリーズ | アミロイドベータ結合タンパク質 |
JP2020521799A (ja) * | 2017-05-30 | 2020-07-27 | ドンペ ファーマスーチシ ソシエタ ペル アチオニ | 細菌性二次感染の治療および/または予防における使用のためのil−8阻害剤 |
Also Published As
Publication number | Publication date |
---|---|
JP3780315B2 (ja) | 2006-05-31 |
US5686070A (en) | 1997-11-11 |
EP0749488A1 (en) | 1996-12-27 |
US5707622A (en) | 1998-01-13 |
US5702946A (en) | 1997-12-30 |
US5677426A (en) | 1997-10-14 |
MX9603773A (es) | 1997-07-31 |
CA2181787A1 (en) | 1995-09-08 |
WO1995023865A1 (en) | 1995-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09509837A (ja) | 炎症性疾患の処置のための抗il−8モノクローナル抗体 | |
KR102662387B1 (ko) | B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도 | |
US6734286B2 (en) | Interleukin-5 specific recombinant antibodies | |
KR100697120B1 (ko) | Il-18 매개 질환의 치료에 유용한 재조합 il-18 길항제 | |
KR101605861B1 (ko) | Il-25에 대한 항체 | |
JPH09512705A (ja) | E−セレクチンに対する抗体 | |
JP2013091636A (ja) | Il−5により媒介される疾病の治療に有用な組み換えil−5アンタゴニスト | |
CN102482352B (zh) | 抗il-17br的抗体 | |
JPH09502708A (ja) | Il4により伝達される疾患の治療に有用な組み換え型il4抗体 | |
JP2001523083A (ja) | Il−5により媒介される疾病の治療に有用な組み換えil−5アンタゴニスト | |
EP0840620B1 (en) | Il-8 antagonists for treatment of asthma | |
JPH08501925A (ja) | 糖蛋白pに対するモノクローナル抗体 | |
JP2002508656A (ja) | 抗−アルファベータ3ヒト化モノクローナル抗体 | |
JP3328277B2 (ja) | Lpsコアに対するモノクローナル抗体 | |
US5858728A (en) | Monoclonal antibody against LPS core | |
US20220325000A1 (en) | Monoclonal antibody which targets tfpi | |
JP2010235447A (ja) | 炎症性サイトカインの抑制剤 | |
ES2391097T3 (es) | Procedimiento de panning en fase en solución usando proteínas señuelo modificadas por ingeniería genética | |
USRE39548E1 (en) | Interleukin-5 specific recombinant antibodies | |
JPH06503956A (ja) | 腫瘍細胞に対する標的決定IgEエフェクター細胞 | |
JP2024105575A (ja) | 特定の腸内細菌の抗体媒介中和による免疫疾患の治療 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040622 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040922 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20041108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050315 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050614 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050801 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050915 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060110 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060125 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20060113 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R154 | Certificate of patent or utility model (reissue) |
Free format text: JAPANESE INTERMEDIATE CODE: R154 |
|
LAPS | Cancellation because of no payment of annual fees |